BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Cidara Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 10:18 am Purchase | 2023-12-31 | 13G | Cidara Therapeutics, Inc. CDTX | BIOTECHNOLOGY VALUE FUND L P | 463,776 9.990% | 120,720 (+35.19%) | Filing |
| 2021-12-16 5:16 pm Purchase | 2021-12-14 | 13G | Cidara Therapeutics, Inc. CDTX | BIOTECHNOLOGY VALUE FUND L P | 343,056 10.300% | 119,982 (+53.79%) | Filing |
| 2021-02-12 4:06 pm Purchase | 2020-12-31 | 13G | Cidara Therapeutics, Inc. CDTX | BIOTECHNOLOGY VALUE FUND L P | 223,075 9.990% | 54,637 (+32.44%) | Filing |
| 2020-02-14 2:52 pm Purchase | 2019-12-31 | 13G | Cidara Therapeutics, Inc. CDTX | BIOTECHNOLOGY VALUE FUND L P | 168,438 9.990% | 23,204 (+15.98%) | Filing |